Contineum Therapeutics (NASDAQ:CTNM) Now Covered by Analysts at Royal Bank of Canada

Royal Bank of Canada initiated coverage on shares of Contineum Therapeutics (NASDAQ:CTNM) in a research report report published on Tuesday, Marketbeat reports. The firm issued an outperform rating and a $30.00 price target on the stock.

CTNM has been the subject of several other research reports. Morgan Stanley assumed coverage on shares of Contineum Therapeutics in a research report on Tuesday. They issued an overweight rating and a $25.00 price objective for the company. Stifel Nicolaus began coverage on shares of Contineum Therapeutics in a report on Tuesday. They issued a buy rating and a $29.00 price target for the company.

Contineum Therapeutics Stock Down 5.4 %

CTNM stock opened at $14.09 on Tuesday. Contineum Therapeutics has a fifty-two week low of $13.65 and a fifty-two week high of $16.06.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).